Remove 2027 Remove Pharmaceuticals Remove Regulations
article thumbnail

Article EMA Thank You What we expect European regulators to do in August and September 2024

Agency IQ

What we expect European regulators to do in August and September 2024 In this recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more.

article thumbnail

Medicinal cannabis: Why more clinical trials and better access is needed

Drug Discovery World

Michael Sassano , CEO at SOMAÍ Pharmaceuticals looks at what’s needed throughout Europe to help increase access to medicinal cannabis and the current state of pharmaceutical research in this area. However, the potential use of cannabis in a pharmaceutical setting is vast. The GW Pharmaceuticals purchase by Jazz for $6.7

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Where is the promise for plant-based medicines? Part 1: Cannabis  

Drug Discovery World

Medical cannabis is often a first-thought when regarding plant-based medicines, but there remains public scepticism, arguably due to the regulations relating to the substance. Jazz Pharmaceuticals has supplied the cannabidiol for the trials at no cost. It’s time to stop borrowing cannabis regulations from other industries.”

article thumbnail

No Sleep ‘Til District Court: Jazz Sues FDA Over Sodium Oxybate Clinical Superiority Determination

FDA Law Blog: Biosimilars

Koblitz — Neither Jazz Pharmaceuticals nor Avadel CNS Pharmaceuticals has taken the battle of sodium oxybate—a drug approved to treat narcolepsy—lying down. Jazz also argues that, notwithstanding the language that instructs FDA to promulgate regulations implementing the clinical superiority provisions at 21 U.S.C.

FDA 52
article thumbnail

Analysis Chemical Thank You Regulatory roundup: EU active on PFAS as Q4 commences

Agency IQ

France In January, the French ecology ministry published a PFAS action plan enumerating six objectives for regulating forever chemicals more comprehensively by 2027. These facilities are uniquely categorized under French law so that they may be regulated with greater oversight. agricultural activity, waste processing).

article thumbnail

Q BioMed’s Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer

The Pharma Data

. With very limited approved first-line pharmaceutical therapies for HCC available today, challenges include drug resistance, adverse side effects, and high costs. billion by 2027. An estimated 700,000 people are diagnosed with HCC each year, with the global market for liver cancer drugs expected to grow to $3.9

FDA 40
article thumbnail

c-LEcta Continues Its Growth in 2020 and Increases Its EBITDA Above Average

The Pharma Data

Positive impetus came from the pharmaceuticals business in particular. Market researchers expect the global market for gene and cell therapy to grow at a CAGR of over 25% through 2027. The Leipzig-based company can look back on a successful 2020 and is planning for a stronger future. Over 85 % of sales now come from products.

Vaccine 52